230
Views
3
CrossRef citations to date
0
Altmetric
Brief Reports

Effect of regular kratom (Mitragyna speciosa Korth.) use on quality of life of people who use kratom

, MBBS, Dr PsychORCID Icon, , BSc & , PhD

References

  • Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (kratom): a survey of the literature. Brain Res Bull. 2016;126(Pt 1):41–46.
  • Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21–27.
  • Saingam D, Assanangkornchai S, Geater AF, Blather Q. Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in Southern Thailand: a qualitative study. Int J Drug Policy. 2013;24(4):351–358.
  • Singh D, Muller CP, Vicknasingam B. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–137.
  • Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21(4):283–288.
  • Grundmann O, Brown PN, Henningfield J, Swogger M, Walsh Z. The therapeutic potential of kratom. Addiction. 2018;113(10):1951–1953.
  • Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23–31.
  • Leong Bin Abdullah MFI, Singh D, Narayanan S, Abdul Rahim A, Vicknasingam B. Socio-demographic characteristics, kratom use and quality of life (QOL) of regular kratom (Mitragyna speciosa Korth.) users. Malaysian J Med Health Sci. 2019;15(3):4–9.
  • Saingam D, Assanangkornchai S, Geater AF, Lerkiatbundit S. Validation of Krathom (Mitragyna speciosa Korth.) Dependence Scale (KDS): a dependence screen for internationally emerging psychoactive substance. Subst Abus. 2014;35(3):276–283.
  • Leong Abdullah MFI, Singh D, Kasinather BV, Azman N. Validation of the Malay version of the Kratom Dependence Scale (KDS) among Malaysian kratom (Mitragyna speciosa Korth.) users. ASEAN J Psychiatry. 2018;19(1):88–97.
  • The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28(3):551–558.
  • Feelemyer JP, Jarlais DCD, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251–258.
  • Lin CY, Chang KC, Wang JD, Lee LJ. Quality of life and its determinants for heroin addicts receiving a methadone maintenance program: comparison with matched referents from the general population. J Formos Med Assoc. 2016;115(9):714–727.
  • Pedrero-Pérez EJ, Group M. Quality of life in patients treated with methadone: The WHOQOL-BREF, psychometric study and application results. An Psicol-Spain. 2018;34(2):251–257.
  • Hasanah CI, Naing L, Rahman AR. World Health Organization Quality of Life Assessment: brief version in Bahasa Malaysia. Med J Malaysia. 2003;58(1):79–88.
  • Strada L, Schmidt CS, Rosenkranz M, et al. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: a cross-sectional study. Subst Abuse Treat Prev Policy. 2019;14(1):2.
  • Gobbens RJJ, Remmen R. The effects of sociodemographic factors on quality of life among people aged 50 years or older are not unequivocal: comparing SF-12, WHOQOL-BREF, and WHOQOL-OLD. Clin Interv Aging. 2019;14:231–239.
  • Eastlack SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9(1):55–69.
  • Swogger MT, Hart E, Erowid F, et al. Experiences of kratom users: a qualitative analysis. J Psychoactive Drugs. 2015;47(5):360–367.
  • Singh V, Mulla N, Wilson JL, et al. Intractable nausea and vomiting in naïve ingestion of kratom for analgesia. Int J Emerg Med. 2020;13(1):42.
  • Singh D, Narayanan S, Müller CP, et al. Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms. J Psychoactive Drugs. 2018;50(5):445–450.
  • Singh D, Muller CP, Vicknasingam BK, Mansor SM. Social functioning of kratom (Mitragyna speciosa) users in Malaysia. J Psychoactive Drugs. 2015;47(2):125–131.
  • Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract. 2011;6(1):44–55.
  • Hallit S, Haddad C, Obeid S, et al. Identification of factors affecting the quality of life among patients with addiction in Lebanon. J Nerv Ment Dis. 2019;207(5):378–383.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.